Company Zeo ScientifiX, Inc.

ZEOX

US68621D2062

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale

Market Closed - OTC Markets Other stock markets 10:04:14 03/05/2024 pm IST			5-day change	1st Jan Change
1.01 ^USD	-15.83%		-22.31%	-0.98%

18/03	Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
05/03	Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL	CI

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Companyâs product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood.

Number of employees: 23

USD in Million	2022	Weight	2023	Weight	Delta
Biological Therapeutics 100.0 %	6	100.0 %	5	100.0 %	-29.78%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	6	100.0 %	5	100.0 %	-29.78%

Managers	Title	Age	Since
Harry Leider CEO	Chief Executive Officer	66	06/23/06
Ian Bothwell DFI	Director of Finance/CFO	63	04/16/04
Howard Golub CTO	Chief Tech/Sci/R&D Officer	71	06/23/06
Jacqueline Domenech COO	Chief Operating Officer	-	20/22/20
David Aciego CTO	Chief Tech/Sci/R&D Officer	-	20/22/20
George Shapiro CTO	Chief Tech/Sci/R&D Officer	63	01/18/01

Members of the board	Title	Age	Since
Ian Bothwell DFI	Director of Finance/CFO	63	04/16/04
Steven Glauser BRD	Director/Board Member	76	23/22/23
Gurvinder Pal Singh BRD	Director/Board Member	62	19/22/19
Harry Leider CEO	Chief Executive Officer	66	06/23/06
Leathem Stearn BRD	Director/Board Member	75	23/22/23
George Shapiro CTO	Chief Tech/Sci/R&D Officer	63	01/18/01
Chuck Bretz CHM	Chairman	66	23/22/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,125,482	3,644,350 ( 59.49 %)	0	59.49 %

Name	Equities	%	Valuation
Ian Bothwell 12.08 %	740,094	12.08 %	1 M $
Bhupendra Kumar Modi 8.163 %	500,000	8.163 %	998 500 $
George Shapiro 6.579 %	403,021	6.579 %	804 833 $
Skycrest Holdings LLC 4.222 %	258,604	4.222 %	516 432 $
Steven Glauser 4.217 %	258,334	4.217 %	515 893 $
Greyt Ventures LLC 4.081 %	250,000	4.081 %	499 250 $
Matthew Sinnreich 2.528 %	154,845	2.528 %	309 225 $
Leathem Stearn 2.041 %	125,000	2.041 %	249 625 $
Harry Leider 0.0857 %	5,247	0.0857 %	10 478 $
Gurvinder Pal Singh 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Skycrest Holdings LLC 50.00 %	50	50.00 %	0 $
Greyt Ventures LLC 50.00 %	50	50.00 %	0 $

ZEO ScientifiX, Inc.

3321 College Avenue Suite 246

33314, Davie

http://www.organicell.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Pharmaceuticals Wholesale

	1st Jan change	Capi.
ZEO SCIENTIFIX, INC.	-0.98%	6.19M
CARDINAL HEALTH, INC.	-1.88%	24.09B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.11%	8.2B
HUADONG MEDICINE CO., LTD	-20.55%	7.97B
SINOPHARM GROUP CO. LTD.	-2.49%	7.84B
H. LUNDBECK A/S	+2.26%	4.66B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.32B
EBOS GROUP LIMITED	+1.41%	4.19B
GALENICA AG	-3.02%	3.89B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.42%	3.62B

Pharmaceuticals Wholesale